期刊
BLOOD
卷 134, 期 21, 页码 1783-1786出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2019002289
关键词
-
类别
资金
- NHLBI NIH HHS [T32 HL116324] Funding Source: Medline
Emapalumab is a fully human immunoglobulin G1 monoclonal antibody directed against interferon-gamma (IFN-gamma), which in November 2018 received the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to HLH therapy. This review will highlight the pathophysiology of primary HLH, the therapeutic rationale for use of IFN-gamma-targeting therapy, and potential limitations to its broader use in the treatment of HLH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据